<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03241303</url>
  </required_header>
  <id_info>
    <org_study_id>H-17007893</org_study_id>
    <nct_id>NCT03241303</nct_id>
  </id_info>
  <brief_title>Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small Intestines</brief_title>
  <acronym>AlfaEx</acronym>
  <official_title>The Role of Glucagon-like Peptide-1 Receptor Signalling in the Glucose-lowering Effect of Increased Carbohydrate Content in the Distal Small Intestines After Meal Ingestion in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigation of GLP-1 signalling in the glucose-lowering effect of increased carbohydrate
      content in the distal small intestines induced by alpha-glucosidase inhibition during meal
      ingestion in patients with type 2 diabetes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim of the study is to investigate whether GLP-1 released as a result of
      increased carbohydrate content in the distal and L cell-rich part of the small intestine
      after a meal affects postprandial plasma glucose levels in patients with type 2 diabetes.
      This will be done by applying an alpha-glucosidase inhibitor (to increase the postprandial
      carbohydrate content in the distal small intestine) and the specific GLP-1 receptor
      antagonist exendin(9-39) (to isolate any GLP-1-mediated effects) during meal tests in
      patients with type 2 diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma glucose</measure>
    <time_frame>240 min</time_frame>
    <description>The primary outcome is the difference between the effect of increased carbohydrate content in the distal part of the small intestine (obtained by inhibiting alpha-glucosidase with acarbose) on postprandial glucose tolerance (as assessed by area under curve (AUC) for plasma glucose during a standardised liquid mixed meal test) with and without blockade of GLP-1 signalling by exendin(9-39).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Glucose Metabolism Disorders</condition>
  <arm_group>
    <arm_group_label>Acarbose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg and 100 mg glucobay tablets. 2 weeks. Other name: Precose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral tablets</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>180 mg. 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exendin (9-39)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Infusion of GLP-1 receptor antagonist as a study tool to block GLP-1 activity on experimental day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placbo Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>9 mg/ml placebo saline infusion on experimental day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acarbose</intervention_name>
    <description>Glucobay tablets on experimental day.</description>
    <arm_group_label>Acarbose</arm_group_label>
    <other_name>Glucobay, Precose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo tablets on experimental day.</description>
    <arm_group_label>Placebo Oral tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exendin (9-39)</intervention_name>
    <description>Infusion of GLP-1 receptor antagonist as a study tool to block GLP-1 activity on experimental day.</description>
    <arm_group_label>Exendin (9-39)</arm_group_label>
    <other_name>Ex(9-39)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Saline</intervention_name>
    <description>9 mg/ml placebo saline infusion on experimental day.</description>
    <arm_group_label>Placbo Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes for at least three months (diagnosed according to the criteria of the
             World Health Organization (WHO)) treated with metformin monotherapy

          -  Caucasian ethnicity

          -  Normal haemoglobin

          -  Age &gt;18 years

          -  BMI &gt;23 kg/m2 and &lt;35 kg/m2

          -  Informed and written consent

        Exclusion Criteria:

          -  Liver disease (alanine aminotransferase (ALAT) and/or serum aspartate aminotransferase
             (ASAT) &gt;2 times normal values) or history of hepatobiliary disorder

          -  Gastrointestinal disease, previous intestinal resection, cholecystectomy or any major
             intra-abdominal surgery

          -  Reduced kidney function or nephropathy (estimated glomerular filtration rate (eGFR)
             &lt;60 ml/min/1.73 m2 (based on serum creatinine) and/or albuminuria

          -  Treatment with medicine that cannot be paused for 12 hours

          -  Intake of antibiotics two months prior to study

          -  Treatment with glucose-lowering drugs other than metformin

          -  Hypo- and hyperthyroidism

          -  Treatment with oral anticoagulants

          -  Active or recent malignant disease

          -  Any treatment or condition requiring acute or sub-acute medical or surgical
             intervention

          -  Lack of effective birth control in premenopausal women

          -  Positive pregnancy test on study days in premenopausal women

          -  Pregnancy

          -  Women who are breastfeeding

          -  Any condition considered incompatible with participation by the investigators

          -  If the subjects receive any antibiotic treatment while included in the study they will
             be excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filip K Knop, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Gentofte, Copenhagen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Niels B Dalsgaard, BSc</last_name>
    <phone>60148753</phone>
    <email>niels.bjoern.dalsgaard@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Filip K Knop, MD, PhD</last_name>
    <phone>26830161</phone>
    <email>filipknop@dadlnet.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Diabetesresearch</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filip K Knop, MD, PhD</last_name>
      <phone>26830161</phone>
      <email>Filipknop@dadlnet.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2017</study_first_submitted>
  <study_first_submitted_qc>August 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2017</study_first_posted>
  <last_update_submitted>August 7, 2017</last_update_submitted>
  <last_update_submitted_qc>August 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Niels Bjørn Dalsgaard</investigator_full_name>
    <investigator_title>Bachelor of Science</investigator_title>
  </responsible_party>
  <keyword>Glp-1</keyword>
  <keyword>alpha-glucosidase inhibitor</keyword>
  <keyword>acarbose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Glucose Metabolism Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Acarbose</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

